Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patrick K. Clark is active.

Publication


Featured researches published by Patrick K. Clark.


Nature Structural & Molecular Biology | 2004

Structures of HIV-1 RT–DNA complexes before and after incorporation of the anti-AIDS drug tenofovir

Steve Tuske; Stefan G. Sarafianos; Arthur D. Clark; Jianping Ding; Lisa K. Naeger; Kirsten L. White; Michael D. Miller; Craig S. Gibbs; Paul L. Boyer; Patrick K. Clark; Gang Wang; Barbara L. Gaffney; Roger A. Jones; Donald M. Jerina; Stephen H. Hughes; Eddy Arnold

Tenofovir, also known as PMPA, R-9-(2-(phosphonomethoxypropyl)adenine, is a nucleotide reverse transcriptase (RT) inhibitor. We have determined the crystal structures of two related complexes of HIV-1 RT with template primer and tenofovir: (i) a ternary complex at a resolution of 3.0 Å of RT crosslinked to a dideoxy-terminated DNA with tenofovir-diphosphate bound as the incoming substrate; and (ii) a RT–DNA complex at a resolution of 3.1 Å with tenofovir at the 3′ primer terminus. The tenofovir nucleotide in the tenofovir-terminated structure seems to adopt multiple conformations. Some nucleoside reverse transcriptase inhibitors, including 3TC and AZT, have elements (handles) that project beyond the corresponding elements on normal dNTPs (the substrate envelope). HIV-1 RT resistance mechanisms to AZT and 3TC take advantage of these handles; tenofovirs structure lacks handles that could protrude through the substrate envelope to cause resistance.


PLOS Pathogens | 2006

Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance?

Paul L. Boyer; Stefan G. Sarafianos; Patrick K. Clark; Eddy Arnold; Stephen H. Hughes

The human immunodeficiency virus type 1 (HIV-1) develops resistance to all available drugs, including the nucleoside analog reverse transcriptase inhibitors (NRTIs) such as AZT. ATP-mediated excision underlies the most common form of HIV-1 resistance to AZT. However, clinical data suggest that when HIV-2 is challenged with AZT, it usually accumulates resistance mutations that cause AZT resistance by reduced incorporation of AZTTP rather than selective excision of AZTMP. We compared the properties of HIV-1 and HIV-2 reverse transcriptase (RT) in vitro. Although both RTs have similar levels of polymerase activity, HIV-1 RT more readily incorporates, and is more susceptible to, inhibition by AZTTP than is HIV-2 RT. Differences in the region around the polymerase active site could explain why HIV-2 RT incorporates AZTTP less efficiently than HIV-1 RT. HIV-1 RT is markedly more efficient at carrying out the excision reaction with ATP as the pyrophosphate donor than is HIV-2 RT. This suggests that HIV-1 RT has a better nascent ATP binding site than HIV-2 RT, making it easier for HIV-1 RT to develop a more effective ATP binding site by mutation. A comparison of HIV-1 and HIV-2 RT shows that there are numerous differences in the putative ATP binding sites that could explain why HIV-1 RT binds ATP more effectively. HIV-1 RT incorporates AZTTP more efficiently than does HIV-2 RT. However, HIV-1 RT is more efficient at ATP-mediated excision of AZTMP than is HIV-2 RT. Mutations in HIV-1 RT conferring AZT resistance tend to increase the efficiency of the ATP-mediated excision pathway, while mutations in HIV-2 RT conferring AZT resistance tend to increase the level of AZTTP exclusion from the polymerase active site. Thus, each RT usually chooses the pathway best suited to extend the properties of the respective wild-type enzymes.


Journal of Virology | 2012

HIV-1 and HIV-2 Reverse Transcriptases: Different Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors.

Paul L. Boyer; Patrick K. Clark; Stephen H. Hughes

ABSTRACT As anti-HIV therapy becomes more widely available in developing nations, it is clear that drug resistance will continue to be a major problem. The related viruses HIV-1 and HIV-2 share many of the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs). However, clinical data suggest that while HIV-1 reverse transcriptase (RT) usually uses an ATP-dependent excision pathway to develop resistance to the nucleoside analog zidovudine (AZT), HIV-2 RT does not appear to use this pathway. We previously described data that suggested that wild-type (WT) HIV-2 RT has a much lower ability to excise AZT monophosphate (AZTMP) than does WT HIV-1 RT and suggested that this is the reason that HIV-2 RT more readily adopts an exclusion pathway against AZT triphosphate (AZTTP), while HIV-1 RT is better able to exploit the ATP-dependent pyrophosphorolysis mechanism. However, we have now done additional experiments, which show that while HIV-1 RT can adopt either an exclusion- or excision-based resistance mechanism against AZT, HIV-2 RT can use only the exclusion mechanism. All of our attempts to make HIV-2 RT excision competent did not produce an AZT-resistant RT but instead yielded RTs that were less able to polymerize than the WT. This suggests that the exclusion pathway is the only pathway available to HIV-2.


Methods in Enzymology | 1995

[15] Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody fab fragment

Arthur D. Clark; Alfredo Jacobo-Molina; Patrick K. Clark; Stephen H. Hughes; Edward Arnold

Publisher Summary This chapter details the methodology used to produce diffraction-quality crystals of a number of Reverse Transcriptase (RT) complexes. The chapter includes description of the purification of the enzyme and of a noninhibitory Fab used in some of the crystallization experiments, because the reproducible preparation of high-quality crystals of HIV-1 RT is critically dependent on the protocols used to purify each of these proteins. The protocol used for the purification of Fab 28 yields one of the isoelectric variants. Crystallization of the RT Fab complex is carried out in hanging-drop vapor diffusion experiments at 4° over reservoirs containing 0.5 ml of crystallization solution. The parent HIV-1 reverse transcriptase used in the preparation of all the crystal forms described in this chapter is a mutant RT that has serine substituted for cysteine at amino acid position 280. It is fully active in polymerization and Ribonuclease H (RNase H) activities and is resistant to oxidative inactivation of RNase H. Crystals of RT that contain one or two amino acid substitutions have been prepared in complexes with Fab28 and dsDNA.


Journal of Virology | 2004

Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase

Paul L. Boyer; Carolyn R. Stenbak; Patrick K. Clark; Maxine L. Linial; Stephen H. Hughes

ABSTRACT Foamy virus (FV) replication, while related to that of orthoretroviruses, differs at a number of steps. Several of these differences involve the reverse transcriptase (RT). There appear to be fewer RTs present in FV than in orthoretroviruses; we previously proposed that the polymerase of FV RT was more active than orthoretroviral RTs to compensate for the numerical difference. Here we present further characterization of the RT of FV. The polymerase activity of FV RT was greater than that of human immunodeficiency virus type 1 RT in a variety of assays. We also examined the RNase H activity of FV RT, and we propose that FV RT has a basic loop in the RNase H domain. Although the sequence of the basic loop of FV RT is different from the basic loop of either Moloney leukemia virus RNase H or Escherichia coli RNase H, the FV RT basic loop appears to have a similar function.


Journal of Virology | 2001

YADD Mutants of Human Immunodeficiency Virus Type 1 and Moloney Murine Leukemia Virus Reverse Transcriptase Are Resistant to Lamivudine Triphosphate (3TCTP) In Vitro

Paul L. Boyer; Hong-Qiang Gao; Patrick K. Clark; Stefan G. Sarafianos; Edward Arnold; Stephen H. Hughes

ABSTRACT When human immunodeficiency virus type 1 (HIV-1) is selected for resistance to 3TC, the methionine normally present at position 184 is replaced by valine or isoleucine. Position 184 is the X of the conserved YXDD motif; positions 185 and 186 form part of the triad of aspartic acids at the polymerase active site. Structural and biochemical analysis of 3TC-resistant HIV-1 reverse transcriptase (RT) led to a model in which a β-branched amino acid at position 184 would act as a steric gate. Normal deoxynucleoside triphosphates (dNTPs) could still be incorporated; the oxathiolane ring of 3TCTP would clash with the β branch of the amino acid at position 184. This model can also explain 3TC resistance in feline immunodeficiency virus and human hepatitis B virus. However, it has been reported (14) that murine leukemia viruses (MLVs) with valine (the amino acid present in the wild type), isoleucine, alanine, serine, or methionine at the X position of the YXDD motif are all resistant to 3TC. We prepared purified wild-type MLV RT and mutant MLV RTs with methionine, isoleucine, and alanine at the X position. The behavior of these RTs was compared to those of wild-type HIV-1 RT and of HIV-1 RT with alanine at the X position. If alanine is present at the X position, both MLV RT and HIV-1 RT are relatively resistant to 3TCTP in vitro. However, the mutant enzymes were impaired relative to their wild-type counterparts; there appears to be steric hindrance for both 3TCTP and normal dNTPs.


Journal of Virology | 2011

Solution Properties of Murine Leukemia Virus Gag Protein: Differences from HIV-1 Gag

Siddhartha A.K. Datta; Xiaobing Zuo; Patrick K. Clark; Stephen J. Campbell; Yun-Xing Wang; Alan Rein

ABSTRACT Immature retrovirus particles are assembled from the multidomain Gag protein. In these particles, the Gag proteins are arranged radially as elongated rods. We have previously characterized the properties of HIV-1 Gag in solution. In the absence of nucleic acid, HIV-1 Gag displays moderately weak interprotein interactions, existing in monomer-dimer equilibrium. Neutron scattering and hydrodynamic studies suggest that the protein is compact, and biochemical studies indicate that the two ends can approach close in three-dimensional space, implying the need for a significant conformational change during assembly. We now describe the properties of the Gag protein of Moloney murine leukemia virus (MLV), a gammaretrovirus. We found that this protein is very different from HIV-1 Gag: it has much weaker protein-protein interaction and is predominantly monomeric in solution. This has allowed us to study the protein by small-angle X-ray scattering and to build a low-resolution molecular envelope for the protein. We found that MLV Gag is extended in solution, with an axial ratio of ∼7, comparable to its dimensions in immature particles. Mutational analysis suggests that runs of prolines in its matrix and p12 domains and the highly charged stretch at the C terminus of its capsid domain all contribute to this extended conformation. These differences between MLV Gag and HIV-1 Gag and their implications for retroviral assembly are discussed.


Journal of Virology | 2001

Cross-Linking of the Fingers Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Template-Primer

Elena N. Peletskaya; Paul L. Boyer; Alex A. Kogon; Patrick K. Clark; Heiko Kroth; Jane M. Sayer; Donald M. Jerina; Stephen H. Hughes

ABSTRACT Cross-linking experiments were performed with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) mutants with unique cysteine residues at several positions (positions 65, 67, 70, and 74) in the fingers subdomain of the p66 subunit. Two approaches were used—photoaffinity cross-linking and disulfide chemical cross-linking (using an oligonucleotide that contained an N2-modified dG with a reactive thiol group). In the former case, cross-linking can occur to any nucleotide in either DNA strand, and in the latter case, a specific cross-link is produced between the template and the enzyme. Neither the introduction of the unique cysteine residues into the fingers nor the modification of these residues with photocross-linking reagents caused a significant decrease in the enzymatic activities of RT. We were able to use this model system to investigate interactions between specific points on the fingers domain of RT and double-stranded DNA (dsDNA). Photoaffinity cross-linking of the template to the modified RTs with Cys residues in positions 65, 67, 70, and 74 of the fingers domain of the p66 subunit was relatively efficient. Azide-modified Cys residues produced 10 to 25% cross-linking, whereas diazirine modified residues produced 5 to 8% cross-linking. Disulfide cross-linking yields were up to 90%. All of the modified RTs preferentially photocross-linked to the 5′ extended template strand of the dsDNA template-primer substrate. The preferred sites of interactions were on the extended template, 5 to 7 bases beyond the polymerase active site. HIV-1 RT is quite flexible. There are conformational changes associated with substrate binding. Cross-linking was used to detect intramolecular movements associated with binding of the incoming deoxynucleoside triphosphate (dNTP). Binding an incoming dNTP at the polymerase active site decreases the efficiency of cross-linking, but causes only modest changes in the preferred positions of cross-linking. This suggests that the interactions between the fingers of p66 and the extended template involve the “open” configuration of the enzyme with the fingers away from the active site rather than the closed configuration with the fingers in direct contact with the incoming dNTP. This experimental approach can be used to measure distances between any site on the surface of the protein and an interacting molecule.


Journal of Virology | 2011

Foamy Retrovirus Integrase Contains a Pol Dimerization Domain Required for Protease Activation

Eun Gyung Lee; Jacqueline Roy; Dana L. Jackson; Patrick K. Clark; Paul L. Boyer; Stephen H. Hughes; Maxine L. Linial

ABSTRACT Unlike orthoretroviruses, foamy retroviruses (FV) synthesize Pol independently of Gag. The FV Pol precursor is cleaved only once between reverse transcriptase (RT) and integrase (IN) by the protease (PR), resulting in a PR-RT and an IN protein. Only the Pol precursor, not the cleaved subunits, is packaged into virions. Like orthoretroviral PRs, FV PR needs to dimerize to be active. Previously, we showed that a Pol mutant lacking IN has defects in PR activity and Pol packaging into virions. We now show that introduction of a leucine zipper (zip) dimerization motif in an IN truncation mutant can restore PR activity, leading to Pol processing in cells. However, these zip mutants neither cleave Gag nor incorporate Pol into virions. We propose that IN is required for Pol dimerization, which is necessary for the creation of a functional PR active site.


Virology | 2013

Mutations in HIV-1 Reverse Transcriptase Cause Misfolding and Miscleavage by the Viral Protease

Linda L. Dunn; Paul L. Boyer; Patrick K. Clark; Stephen H. Hughes

Previous work on mutations in the thumb of HIV-1 reverse transcriptase (RT) showed that the majority of the mutant RTs were degraded (by the viral protease) to various extents in virions. This degradation was, in most cases, temperature sensitive, and presumably was due to a partial unfolding of the protein at 37°C. We used recombinant proteins to investigate the effects of the mutations on the thermal stability and proteolytic degradation of RT. Both subunits contribute to the stability of RT. In general, the differences in stability between the mutants and WT were greater if the mutation was in p51 rather than p66. Expressing the Pol polyprotein containing the RT mutants in Escherichia coli produced results similar to what was seen in virions; the mutant RTs were misfolded and/or degraded at 37°C, but were better folded and processed at 30°C.

Collaboration


Dive into the Patrick K. Clark's collaboration.

Top Co-Authors

Avatar

Stephen H. Hughes

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Paul L. Boyer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Arthur D. Clark

Center for Advanced Biotechnology and Medicine

View shared research outputs
Top Co-Authors

Avatar

Edward Arnold

Center for Advanced Biotechnology and Medicine

View shared research outputs
Top Co-Authors

Avatar

Eddy Arnold

Center for Advanced Biotechnology and Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan Rein

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Siddhartha A.K. Datta

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Alfredo Jacobo-Molina

Center for Advanced Biotechnology and Medicine

View shared research outputs
Top Co-Authors

Avatar

Donald M. Jerina

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge